Arrayit Corporation Reports Strong Surge In Customer Demand For The Company's Leading Edge Life Sciences Microarray Instruments
SUNNYVALE, Calif., May 10, 2010 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTCBB:ARYC), a leader in life sciences and healthcare technology, reports today a strong surge in customer demand for the company's leading edge life sciences microarray instruments. On Friday May 7th, the company quoted 17 instruments representing $1.2M in total revenue. The increase coincides directly with the first deliveries of the new Arrayit 2010 catalog sent by mail to 11,000 life sciences professionals worldwide.
Arrayit Corporation CEO Rene Schena stated, "We are pleased by the positive and immediate customer response. Our commitment to life sciences instrumentation is an important driver for revenues growth in 2010."
Arrayit's life sciences instruments empower scientists and clinicians to explore fundamental challenges in basic research, agriculture, and medicine, including deciphering the molecular basis of human diseases. Arrayit microarrays are manufactured by depositing nearly invisible spots of genes, proteins, and patient DNAs onto glass substrates, and then reacting the microarrays with labeled samples isolated from living cells and other sources. The microarrays are processed and read using computer-controlled hybridization stations and high-speed fluorescence scanners to produce digital genomic and proteomic data. Arrayit's instruments are "best-in-class" based on unparalleled performance, versatility, and ease-of-use.Arrayit Corporation President and Chief Science Officer Mark Schena said, "The widely adopted Arrayit platform with its unique technological attributes, including the proprietary H25K complete human genome chip, provides results that are unrivaled by other platforms. Arrayit microarrays and instruments offer richer content and greater sensitivity than competing platforms, and these attributes have allowed us to discover the world's only definitive pre-symptomatic biomarkers for ovarian cancer and Parkinson's Disease, as well as a new pharmaceutically important pathway in human biology that will be the subject of future announcements." About Arrayit Corporation Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. Arrayit now offers over 650 products and services to a customer base of more than 10,000 clinics and research facilities and more than 5,000 laboratories worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit www.arrayit.com for more information. Safe Harbor Statement We have identified forward-looking statements by using words such as "expect," "believe," and "should." Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K for the fiscal year ended December 31, 2009.
CONTACT: Arrayit Corporation Investor Relations 408-744-1331 email@example.com
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV